MicroRNA-155-5p regulates the Th1/Th2 cytokines expression and the apoptosis of group 2 innate lymphoid cells via targeting TP53INP1 in allergic rhinitis

Zhu, Yaqiong; Yuan, Fan; Fu, Yanpeng; Zhu, Xinhua; Wang, Zhi; Wu, Shuhong; Guo, Liqing; Zhang, Qingkun; Mou, Xinqi; Liu, Yuehui

doi:10.1016/j.intimp.2021.108317

Cited by 9 publications

(12 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In AR, this regulatory mechanism has also been widely reported. MiRNA-155-5p targeted TP53INP1 to aggravate AR through promoting inflammatory response [29]. In current study, we identified that ETS1 was a targeted gene of miR-193b-3p, which was evidenced by bioinformatics analysis and luciferase assay.…”

Section: Discussionmentioning

confidence: 68%

MiR-193b-3p Regulates TLR4 Expression to Inhibit Inflammation by Targeting ETS1 in Allergic Rhinitis

Jing

Xie

Huang

et al. 2023

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Introduction: Allergic rhinitis (AR) is identified as a multifactorial disease caused by the interaction of genes and surroundings, which is difficult to cure. MicroRNAs were reported to be engaged in AR development. Here, we aimed to seek the anti-inflammatory effects and regulatory mechanism of miR-193b-3p in AR. Methods: Mucosal tissues from AR patients and healthy volunteers were collected, and human nasal epithelial cells (HNECs) were treated with IL-13 to establish a cell model of AR. The gene expression of miR-193b-3p, ETS1, TLR4, GM-CSF, eotaxin, and MUC5AC was determined by RT-qPCR. The protein levels of ETS1 and TLR4 were examined using Western blot. Enzyme-linked immunosorbent assay was performed to measure protein concentration of GM-CSF, eotaxin, and MUC5AC in cell supernatant. Dual luciferase assay was applied to verify the interaction among miR-193b-3p, ETS1, and TLR4. Results: The expression of miR-193b-3p was declined in clinical samples from AR patients and in IL-13-induced HNECs, while the mRNA and protein levels of ETS1 and TLR4 were elevated. MiR-193b-3p overexpression or ETS1 silencing notably decreased the mRNA and protein levels of GM-CSF, eotaxin, and MUC5AC in IL-13-treated HNECs. Mechanistically, miR-193b-3p directly combined with ETS1 to silence ETS1 expression. ETS1 promoted the transcriptional activity of TLR4 through interacting with TLR4 promoter. Furthermore, rescue experiments revealed that ETS1 overexpression abolished miR-193b-3p sufficiency-mediated suppression of the mRNA and protein levels of GM-CSF, eotaxin, and MUC5AC in IL-13-treated HNECs. Similarly, TLR4 overexpression compromised the inhibitory impacts of ETS1 downregulation on the mRNA and protein levels of GM-CSF, eotaxin, and MUC5AC in IL-13-induced HNECs. Discussion: MiR-193b-3p repressed IL-13-induced inflammatory response in HNECs by suppressing ETS1/TLR4 axis, which indicated that miR-193b-3p might be a therapeutic target for AR treatment.

show abstract

Section: Discussionmentioning

confidence: 68%

MiR-193b-3p Regulates TLR4 Expression to Inhibit Inflammation by Targeting ETS1 in Allergic Rhinitis

Jing

Xie

Huang

et al. 2023

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…The symptoms of AR mostly result from the over inflammatory response (Khan, 2014). At present, it is generally believed that the inflammatory response caused by the imbalance of Th1/Th2 cytokines plays a crucial role in the pathogenesis of AR (Chen et al, 2020;Dong et al, 2021;Sun et al, 2020;Zhu et al, 2021). Our enrichment results revealed that the prescriptions involved terms related to inflammatory response and Interleukins.…”

Section: Discussionmentioning

confidence: 77%

A randomized, double-blinded, superiority clinical trial to compare two dimensions of traditional medical precision medicine for allergic rhinitis: syndrome differentiation-based treatment or staging treatment?

Li¹,

Fu²,

Chen³

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Traditional Chinese medicine (TCM) is widely used for allergic rhinitis (AR) treatment. The precision medicine of TCM treatment included 1) syndrome differentiation-based treatment (SDT) and 2) staging-based prescription modifying treatment (ST). This study conducted a randomized, controlled, double-blinded, superiority, non-inferiority, and equivalence clinical trial to compare their therapeutic effect on AR.Methods Participants were diagnosed with TCM syndrome differentiation. Participants in the SDT group received a 6-week regular SDT with different prescriptions. Participants in the ST group received a 6-week ST in which every two weeks were defined as a stage (early, mid, and late) with different prescriptions. The prescriptions were all recommended by the Chinese National Administration of TCM and their therapeutic effects were supported by both classics of TCM literature and modern reference. The symptoms and constitutions related to AR patients were assessed at week 0 and week 6 and followed up after 1 year. SDT and ST in different gender, ages, and syndrome differentiation groups were compared. All the prescriptions in this study were analyzed using TCM components and property analysis and bioinformatic analysis.Results 158 SDT and 159 ST patients were included in the analysis. Both SDT and ST significantly improved symptoms and constitution of AR. ST had a better therapeutic effect than SDT except for “Lung meridian heat” patients. Although gender might not affect the difference between SDT and ST, age might be an impact factor. The TCM components and property analysis and bioinformatic analysis provide information to better understand these classical prescriptions.Conclusion For most AR patients, the syndrome differentiation based on disease alteration course over the treatment time was more therapy-critical than the syndrome differentiation based on patients’ constitution (or disease subtypes) and syndrome differentiation type and age are affecting factors.

show abstract

“…miRNA-155-5p showed high expression in allergic rhinitis. Studies have demonstrated that TP53INP1 may have an anti-inflammatory role because it can inhibit the nuclear factor-κ B (NF-κB) signaling pathway in patients with allergic rhinitis, but the specific mechanism is largely unknown ( 39 ).…”

Section: Regulation Of Mrna Stability Can Affect Pulmonary Fibrosis A...mentioning

confidence: 99%

Regulation of mRNA stability contributes to the function of innate lymphoid cells in various diseases

et al. 2023

View full text Add to dashboard Cite

Innate lymphoid cells (ILCs) are important subsets of innate immune cells that regulate mucosal immunity. ILCs include natural killer cells, innate lymphoid cells-1 (ILC1s), ILC2s, and ILC3s, which have extremely important roles in the immune system. In this review, we summarize the regulation of mRNA stability mediated through various factors in ILCs (e.g., cytokines, RNA-binding proteins, non-coding RNAs) and their roles in mediating functions in different ILC subsets. In addition, we discuss potential therapeutic targets for diseases such as chronic obstructive pulmonary disease, cancer, and pulmonary fibrosis by regulation of mRNA stability in ILCs, which may provide novel directions for future clinical research.

show abstract

MicroRNA-155-5p regulates the Th1/Th2 cytokines expression and the apoptosis of group 2 innate lymphoid cells via targeting TP53INP1 in allergic rhinitis

Cited by 9 publications

References 36 publications

MiR-193b-3p Regulates TLR4 Expression to Inhibit Inflammation by Targeting ETS1 in Allergic Rhinitis

MiR-193b-3p Regulates TLR4 Expression to Inhibit Inflammation by Targeting ETS1 in Allergic Rhinitis

A randomized, double-blinded, superiority clinical trial to compare two dimensions of traditional medical precision medicine for allergic rhinitis: syndrome differentiation-based treatment or staging treatment?

Regulation of mRNA stability contributes to the function of innate lymphoid cells in various diseases

Contact Info

Product

Resources

About